Skip to main content
SpringerLink
Log in

Targeting of EGFR Induced Signaling Network in Hepatocellular Carcinoma

  • Chapter
  • First Online:
Molecular Oncology: Underlying Mechanisms and Translational Advancements

Abstract

Hepatocellular carcinoma is a multifaceted and genomically complex disease and rapidly emerging experimental evidence has started to shed light on wide ranging molecular mechanisms which underlie its development and progression. It is now known that Overexpression of oncogenes, inactivation of tumor suppressor genes, dysregulation of spatio-temporally controlled intracellular signaling cascades, genetic/epigenetic mutations, loss of apoptosis and intra-tumor heterogeneity contribute significantly. Research over the years has gradually revealed intricate role of intracellular signaling cascades both in growth, development and cancer. Misrepresentation of EGFR induced intracellular signaling has been shown to fuel cancer development and progression. We partition this review into how EGFR modulates protein machinery in hepatocellular carcinoma and also summarize most recent updates on preclinical and clinical trials. Better and deeper understanding of the molecular mechanisms of HCC will be helpful in getting a step closer to individualized medicine.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 89.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Chong CR, Jänne PA (2013) The quest to overcome resistance to EGFR-targeted therapies in cancer. Nat Med 19(11):1389–1400. doi:10.1038/nm.3388

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. Wheeler DL, Dunn EF, Harari PM (2010) Understanding resistance to EGFR inhibitors-impact on future treatment strategies. Nat Rev Clin Oncol 7(9):493–507. doi:10.1038/nrclinonc.2010.97

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Ye QH, Zhu WW, Zhang JB, Qin Y, Lu M, Lin GL, Guo L, Zhang B, Lin ZH, Roessler S, Forgues M, Jia HL, Lu L, Zhang XF, Lian BF, Xie L, Dong QZ, Tang ZY, Wang XW, Qin LX (2016) GOLM1 modulates EGFR/RTK cell-surface recycling to drive hepatocellular carcinoma metastasis. Cancer Cell 30(3):444–458

    Article  CAS  PubMed  Google Scholar 

  4. Leng C, Zhang ZG, Chen WX, Luo HP, Song J, Dong W, Zhu XR, Chen XP, Liang HF, Zhang BX (2016) An integrin beta4-EGFR unit promotes hepatocellular carcinoma lung metastases by enhancing anchorage independence through activation of FAK-AKT pathway. Cancer Lett 376(1):188–196

    Article  CAS  PubMed  Google Scholar 

  5. Huan H, Wen X, Chen X, Wu L, Liu W, Habib NA, Bie P, Xia F (2016) C/EBPα short-activating RNA suppresses metastasis of hepatocellular carcinoma through inhibiting EGFR/β-catenin signaling mediated EMT. PLoS One 11(4):e0153117

    Article  PubMed  PubMed Central  Google Scholar 

  6. Steinway SN, Dang H, You H, Rountree CB, Ding W (2015) The EGFR/ErbB3 pathway acts as a compensatory survival mechanism upon c-Met inhibition in human c-Met+ hepatocellular carcinoma. PLoS One 10(5):e0128159

    Article  PubMed  PubMed Central  Google Scholar 

  7. Gong C, Zhang J, Zhang L, Wang Y, Ma H, Wu W, Cui J, Wang Y, Ren Z (2015) Dynamin2 downregulation delays EGFR endocytic trafficking and promotes EGFR signaling and invasion in hepatocellular carcinoma. Am J Cancer Res 5(2):702–713

    CAS  PubMed  PubMed Central  Google Scholar 

  8. Wang ZC, Gao Q, Shi JY, Guo WJ, Yang LX, Liu XY, Liu LZ, Ma LJ, Duan M, Zhao YJ, Wu YN, Gao DM, Wang XY, Shi GM, Ding ZB, Ke AW, Tang QQ, Cao Y, Zhou J, Fan J (2015) Protein tyrosine phosphatase receptor S acts as a metastatic suppressor in hepatocellular carcinoma by control of epithermal growth factor receptor-induced epithelial-mesenchymal transition. Hepatology 62(4):1201–1214

    Article  CAS  PubMed  Google Scholar 

  9. Lin BY, Xiao CX, Zhao WX, Xiao L, Chen X, Li P, Wang XM (2015) Enoyl-coenzyme A hydratase short chain 1 silencing attenuates the proliferation of hepatocellular carcinoma by inhibiting epidermal growth factor signaling in vitro and in vivo. Mol Med Rep 12(1):1421–1428

    CAS  PubMed  Google Scholar 

  10. Huang MJ, Hu RH, Chou CH, Hsu CL, Liu YW, Huang J, Hung JS, Lai IR, Juan HF, Yu SL, Wu YM, Huang MC (2015) Knockdown of GALNT1 suppresses malignant phenotype of hepatocellular carcinoma by suppressing EGFR signaling. Oncotarget. 6(8):5650–5665

    Article  PubMed  PubMed Central  Google Scholar 

  11. Fang Z, Zhou L, Jiang S, Cao L, Yu L (2015) UNC50 prompts G1/S transition and proliferation in HCC by regulation of epidermal growth factor receptor trafficking. PLoS One 10(3):e0119338

    Article  PubMed  PubMed Central  Google Scholar 

  12. Hung CM, Huang WC, Pan HL, Chien PH, Lin CW, Chen LC, Chien YF, Lin CC, Leow KH, Chen WS, Chen JY, Ho CY, Hou PS, Chen YJ (2014) Hepatitis B virus X upregulates HuR protein level to stabilize HER2 expression in hepatocellular carcinoma cells. Biomed Res Int 2014:827415

    PubMed  PubMed Central  Google Scholar 

  13. Li SX, Liu LJ, Dong LW, Shi HG, Pan YF, Tan YX, Zhang J, Zhang B, Ding ZW, Jiang TY, Hu HP, Wang HY (2014) CKAP4 inhibited growth and metastasis of hepatocellular carcinoma through regulating EGFR signaling. Tumour Biol 35(8):7999–8005

    Article  CAS  PubMed  Google Scholar 

  14. Luo X, Xie H, Long X, Zhou M, Xu Z, Shi B, Jiang H, Li Z (2013) EGFRvIII mediates hepatocellular carcinoma cell invasion by promoting S100 calcium binding protein A11 expression. PLoS One 8(12):e83332

    Article  PubMed  PubMed Central  Google Scholar 

  15. Wang L, Sun H, Wang X, Hou N, Zhao L, Tong D, He K, Yang Y, Song T, Yang J, Huang C (2016) EGR1 mediates miR-203a suppress the hepatocellular carcinoma cells progression by targeting HOXD3 through EGFR signaling pathway. Oncotarget 7(29):45302–45316. doi:10.18632/oncotarget.9605

    PubMed  PubMed Central  Google Scholar 

  16. Wang X, Zhang W, Tang J, Huang R, Li J, Xu D, Xie Y, Jiang R, Deng L, Zhang X, Chai Y, Qin X, Sun B (2016) LINC01225 promotes occurrence and metastasis of hepatocellular carcinoma in an epidermal growth factor receptor-dependent pathway. Cell Death Dis 7:e2130. doi:10.1038/cddis.2016.26

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Higuchi T, Todaka H, Sugiyama Y, Ono M, Tamaki N, Hatano E, Takezaki Y, Hanazaki K, Miwa T, Chin See LS, Morisawa K, Tsuda M, Taniguchi T, Sakamoto S (2016) Suppression of miR-7 biogenesis by NF90-NF45 controls cell proliferation in hepatocellular carcinoma. J Biol Chem 291(40):21074–21084. doi:10.1074/jbc.M116.748210

    Article  CAS  PubMed  Google Scholar 

  18. Zou CD, Zhao WM, Wang XN, Li Q, Huang H, Cheng WP, Jin JF, Zhang H, Wu MJ, Tai S, Zou CX, Gao X (2016) MicroRNA-107: a novel promoter of tumor progression that targets the CPEB3/EGFR axis in human hepatocellular carcinoma. Oncotarget. 7(1):266–278

    PubMed  Google Scholar 

  19. Qi HL, Li CS, Qian CW, Xiao YS, Yuan YF, Liu QY, Liu ZS (2016) The long noncoding RNA, EGFR-AS1, a target of GHR, increases the expression of EGFR in hepatocellular carcinoma. Tumour Biol 37(1):1079–1089

    Article  CAS  PubMed  Google Scholar 

  20. Chen W, Qiu Y (2015) Ginsenoside Rh2 targets EGFR by up-regulation of miR-491 to enhance anti-tumor activity in hepatitis B virus-related hepatocellular carcinoma. Cell Biochem Biophys 72(2):325–331

    Article  CAS  PubMed  Google Scholar 

  21. Huang S, He R, Rong M, Dang Y, Chen G (2014) Synergistic effect of MiR-146a mimic and cetuximab on hepatocellular carcinoma cells. Biomed Res Int 2014:384121

    PubMed  PubMed Central  Google Scholar 

  22. Fang T, Hou J, He M, Wang L, Zheng M, Wang X, Xia J (2016) Actinidia chinensis Planch root extract (acRoots) inhibits hepatocellular carcinoma progression by inhibiting EP3 expression. Cell Biol Toxicol 32(6):499–511

    Article  PubMed  Google Scholar 

  23. Liu X, Tian S, Liu M, Jian L, Zhao L (2016) Wogonin inhibits the proliferation and invasion, and induces the apoptosis of HepG2 and Bel7402 HCC cells through NF-κB/Bcl-2, EGFR and EGFR downstream ERK/AKT signaling. Int J Mol Med 38(4):1250–1256

    PubMed  Google Scholar 

  24. Qian L, Liu Y, Xu Y, Ji W, Wu Q, Liu Y, Gao Q, Su C (2015) Matrine derivative WM130 inhibits hepatocellular carcinoma by suppressing EGFR/ERK/MMP-2 and PTEN/AKT signaling pathways. Cancer Lett 368(1):126–134

    Article  CAS  PubMed  Google Scholar 

  25. Gu HR, Park SC, Choi SJ, Lee JC, Kim YC, Han CJ, Kim J, Yang KY, Kim YJ, Noh GY, No SH, Jeong JH (2015) Combined treatment with silibinin and either sorafenib or gefitinib enhances their growth-inhibiting effects in hepatocellular carcinoma cells. Clin Mol Hepatol 21(1):49–59

    Article  PubMed  PubMed Central  Google Scholar 

  26. Ding J, Wen W, Xiang D, Yin P, Liu Y, Liu C, He G, Cheng Z, Yin J, Sheng C, Zhang W, Nan F, Ye W, Zhang X, Wang H (2015) ψ-Bufarenogin, a novel anti-tumor compound, suppresses liver cancer growth by inhibiting receptor tyrosine kinase-mediated signaling. Oncotarget 6(13):11627–11639

    Article  PubMed  PubMed Central  Google Scholar 

  27. Yan YY, Guo Y, Zhang W, Ma CG, Zhang YX, Wang C, Wang HX (2014) Celastrol enhanced the anticancer effect of lapatinib in human hepatocellular carcinoma cells in vitro. J BUON 19(2):412–418

    PubMed  Google Scholar 

  28. Chang L, Wang G, Jia T, Zhang L, Li Y, Han Y, Zhang K, Lin G, Zhang R, Li J, Wang L (2016) Armored long non-coding RNA MEG3 targeting EGFR based on recombinant MS2 bacteriophage virus-like particles against hepatocellular carcinoma. Oncotarget. 7(17):23988–24004

    PubMed  PubMed Central  Google Scholar 

  29. Poojari R, Kini S, Srivastava R, Panda D (2015) A chimeric cetuximab-functionalized corona as a potent delivery system for microtubule-destabilizing nanocomplexes to hepatocellular carcinoma cells: a focus on EGFR and tubulin intracellular dynamics. Mol Pharm 12(11):3908–3923

    Article  CAS  PubMed  Google Scholar 

  30. Jiang J, Chen H, Yu C, Zhang Y, Chen M, Tian S, Sun C (2015) The promotion of salinomycin delivery to hepatocellular carcinoma cells through EGFR and CD133 aptamers conjugation by PLGA nanoparticles. Nanomedicine (Lond) 10(12):1863–1879

    Article  CAS  Google Scholar 

  31. Bondì ML, Azzolina A, Craparo EF, Botto C, Amore E, Giammona G, Cervello M (2014) Entrapment of an EGFR inhibitor into nanostructured lipid carriers (NLC) improves its antitumor activity against human hepatocarcinoma cells. J Nanobiotechnol 12:21. doi:10.1186/1477-3155-12-21

    Article  Google Scholar 

  32. Goyal L, Wadlow RC, Blaszkowsky LS, Wolpin BM, Abrams TA, McCleary NJ, Sheehan S, Sundaram E, Karol MD, Chen J, Zhu AX (2015) A phase I and pharmacokinetic study of ganetespib (STA-9090) in advanced hepatocellular carcinoma. Invest New Drugs 33(1):128–137

    Article  CAS  PubMed  Google Scholar 

  33. Hsu CH, Kang YK, Yang TS, Shun CT, Shao YY, Su WC, Sandoval-Tan J, Chiou TJ, Jin K, Hsu C, Cheng AL (2013) Bevacizumab with erlotinib as first-line therapy in Asian patients with advanced hepatocellular carcinoma: a multicenter phase II study. Oncology 85(1):44–52

    Article  CAS  PubMed  Google Scholar 

  34. Chen YJ, Chi CW, Su WC, Huang HL (2014) Lapatinib induces autophagic cell death and inhibits growth of human hepatocellular carcinoma. Oncotarget. 5(13):4845–4854

    Article  PubMed  PubMed Central  Google Scholar 

  35. Jiang H, Dong Q, Luo X, Shi B, Wang H, Gao H, Kong J, Zhang J, Li Z (2014) The monoclonal antibody CH12 augments 5-fluorouracil-induced growth suppression of hepatocellular carcinoma xenografts expressing epidermal growth factor receptor variant III. Cancer Lett 342(1):113–120

    Article  CAS  PubMed  Google Scholar 

  36. Blivet-Van Eggelpoël MJ, Chettouh H, Fartoux L, Aoudjehane L, Barbu V, Rey C, Priam S, Housset C, Rosmorduc O, Desbois-Mouthon C (2012) Epidermal growth factor receptor and HER-3 restrict cell response to sorafenib in hepatocellular carcinoma cells. J Hepatol 57(1):108–115

    Article  PubMed  Google Scholar 

  37. Wu JR, Hu CT, You RI, Ma PL, Pan SM, Lee MC, Wu WS (2015) Preclinical trials for prevention of tumor progression of hepatocellular carcinoma by LZ-8 targeting c-Met dependent and independent pathways. PLoS One 10(1):e0114495

    Article  PubMed  PubMed Central  Google Scholar 

  38. Li T, Dong ZR, Guo ZY, Wang CH, Zhi XT, Zhou JW, Li DK, Chen ZT, Chen ZQ, Hu SY (2015) Mannose-mediated inhibitory effects of PA-MSHA on invasion and metastasis of hepatocellular carcinoma via EGFR/Akt/IκBβ/NF-κB pathway. Liver Int 35(4):1416–1429

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Botany Department, Faculty of Science, İstanbul University, Suleymaniye, Istanbul, 34460, Turkey

    Aliye Aras Perk

  2. Department of Plant Sciences, Quaid e Azam University, Islamabad, Pakistan

    Riffat Batool

  3. Department of Zoology, PMAS-Arid Agriculture University, Rawalpindi, Pakistan

    Sobia Kanwal

  4. Department of Experimental Therapy, Hirszfeld Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, R. Weigl 12, Wroclaw, 53-114, Poland

    Edyta Pawlak-Adamska

  5. Department of Human Evolutionary Biology, Institute of Anthropology, Adam Mickiewicz University, Umultowska 89, Poznan, 61-614, Poland

    Oskar Nowak

  6. Department of Biochemistry, PMAS-Arid Agriculture University, Rawalpindi, Pakistan

    Muhammad Sheeraz Ahmad

  7. Institute of Biomedical and Genetic Engineering (IBGE), G-9/1 Mauve Area, Islamabad, Pakistan

    Qaisar Mansoor, Ammad Ahmad Farooqi & Muhammad Ismail

  8. Laboratorio de Investigación Clínica, Unidad Académica de Medicina, Universidad Autónoma de Guerrero, Av. Solidaridad S/N Col. Hornos Insurgentes, Acapulco, Guerrero, Mexico

    Mirna Azalea Romero

  9. UVAS, Lahore, Pakistan

    Madeeha Awan

Authors
  1. Aliye Aras Perk
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Riffat Batool
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Sobia Kanwal
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Edyta Pawlak-Adamska
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Oskar Nowak
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Muhammad Sheeraz Ahmad
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Qaisar Mansoor
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Mirna Azalea Romero
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Madeeha Awan
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Ammad Ahmad Farooqi
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Muhammad Ismail
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to Mirna Azalea Romero or Ammad Ahmad Farooqi .

Editor information

Editors and Affiliations

  1. Institute of Biomedical and Genetic Engineering (IBGE), Islamabad, Pakistan

    Ammad Ahmad Farooqi

  2. Institute of Biomedical and Genetic Engineering (IBGE), Islamabad, Pakistan

    Muhammad Ismail

Rights and permissions

Reprints and permissions

Copyright information

© 2017 Springer International Publishing AG

About this chapter

Cite this chapter

Perk, A.A. et al. (2017). Targeting of EGFR Induced Signaling Network in Hepatocellular Carcinoma. In: Farooqi, A., Ismail, M. (eds) Molecular Oncology: Underlying Mechanisms and Translational Advancements. Springer, Cham. https://doi.org/10.1007/978-3-319-53082-6_7

Download citation

Publish with us

Policies and ethics

Search

Navigation